Skip to Content
Merck
  • Increased epicardial adipose tissue is associated with coronary artery disease and major adverse cardiovascular events.

Increased epicardial adipose tissue is associated with coronary artery disease and major adverse cardiovascular events.

Atherosclerosis (2014-12-03)
Fereshteh Hajsadeghi, Vahid Nabavi, Ajay Bhandari, Andrew Choi, Hunter Vincent, Ferdinand Flores, Matthew Budoff, Naser Ahmadi
ABSTRACT

Increased-epicardial-adipose tissue (EAT) is associated with the presence and severity of subclinical-atherosclerosis. This study investigates the long-term clinical-outcome of subjects with and without increased-EAT. Two hundred and forty-five subjects, aged 61 ± 9 years and 34% women underwent clinically-indicated computed-tomography-angiography (CTA), and body-surface-area adjusted EAT was measured and were followed prospectively. CTA-diagnosed coronary-artery-disease (CAD) was defined as obstructive (luminal-stenosis ≥ 50%), non-obstructive (luminal-stenosis: 1-49%) and zero-obstruction. Major-adverse-cardiac-event (MACE) was defined as myocardial-infarction or cardiovascular-death. EAT increased significantly from subjects with zero-obstruction-coronaries (93 ± 37 cm(3)/m(2)) to non-obstructive-CAD (132 ± 25 cm(3)/m(2)) to obstructive-CAD (145 ± 35 cm(3)/m(2)) (P = 0.01). During the 48-month follow-up, the event-rate was 8.6% (21). The event free survival-rate decreased significantly from 99% in the lowest-quartile to 86.6% in the highest-quartile of EAT. After adjustment for risk-factors, the hazard ratio of MACE was 1.4, 3.1 and 5.7 in lower mid-, upper mid- and highest-quartiles of EAT as compared to lowest-quartile of EAT (P < 0.05). Increased EAT is directly associated with CAD and predicts MACE independent of the age, gender and conventional-risk-factors.

MATERIALS
Product Number
Brand
Product Description

USP
Iopamidol, United States Pharmacopeia (USP) Reference Standard
Iopamidol, European Pharmacopoeia (EP) Reference Standard